Closed · HT9425-23-NFRP-CTA · CFDA 12.420 · Discretionary
DoD Neurofibromatosis Clinical Trial Award
Federal grant opportunity posted by Dept. of the Army -- USAMRAA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 5, 2023
- Close date
- 1
- Expected awards
The verdict
DoD Neurofibromatosis Clinical Trial Award is a closed discretionary listing from Dept. of the Army -- USAMRAA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 1
- expected award
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoD Neurofibromatosis Clinical Trial Award - is cataloged under number HT9425-23-NFRP-CTA and tied to CFDA assistance listing 12.420, posted by Dept. of the Army -- USAMRAA. Grants.gov currently shows the opportunity as closed, first posted on May 22, 2023 and last updated on August 10, 2023. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $1.6 million in total estimated funding for this announcement. It expects to issue 1 award. If the agency funds the expected 1 award from the $1.6 million estimated pool, the average award works out to roughly $1.6 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on October 5, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
October 5, 2023
Posted
May 22, 2023
Est. Total Funding
$1,600,000
Expected Awards
1
Instrument
Grant
Description
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.The vision of the FY23 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and Schwannomatosis.Areas of Emphasis: The FY23 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the Areas of Emphasis listed below. All applications are also encouraged to include materials and data from diverse populations in their research.• NF2 and Schwannomatosis-related areas (e.g., hearing, balance, schwannoma, ependymoma, meningioma, LZTR1, SMARCB1)• Endpoint validation, biomarker discovery, and technological innovation for assessments• Application of data science• Non-tumor manifestations not limited to:o Paino Cognitive manifestationso Sleep
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Dept. of the Army -- USAMRAA
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Department of Defense HIV/AIDS Prevention Program
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |